New Report on Toxic Posterior Segment Syndrome Following Dropless Cataract Surgery with Compounded Triamcinolone-Moxifloxacin
In 2017, an unexpected cluster of patients in the Dallas area who had recently undergone dropless cataract surgery (DLCS) developed toxic posterior segment syndrome (TPSS), a rare, non-infectious inflammatory condition affecting the
read more
Dr. Abbey Reports on Latest Study Evaluating DME Outcomes After Switching from Faricimab-svoa to High-dose Aflibercept
In the latest issue of Ophthalmic Surgery, Lasers & Imaging Retina, Texas Retina’s Ashkan M. Abbey, MD, co-authored a retrospective study evaluating the effectiveness of high-dose aflibercept 8 mg (Eylea HD) in
read more
Dr. Abbey Presents ARCHER II Clinical Trial Data at The Retina Society Annual Scientific Meeting
Texas Retina’s Ashkan Abbey, MD, presented baseline characteristics of participants in the Phase 3 ARCHER II clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) at the 59th
read more
Texas Retina Dallas Research Team Recognized for Highest Site Enrollment Globally in Geographic Atrophy Clinical Trial
Under the leadership of Principal Investigator Dr. Ashkan M. Abbey, the Texas Retina Dallas research team was recently named the top enroller for Part I of the DFI18231 study, which is evaluating
read more
Texas Retina’s Anna Brown Selected for Trials InSight Research Coordinator Executive Committee
Texas Retina Clinical Research Coordinator Anna Brown was recently selected by Trials InSight to serve on its new Research Coordinator Executive Committee. Trials InSight is a first-of-its-kind congress focused on the future
read more
National Retina Research Network Invites Dr. Shami to Discuss Current Study Protocols
The U.S.-based, federally funded DRCR Retina Network recently invited Texas Retina’s Michel J. Shami, MD, to provide investigators with updates on three of the network’s current studies: Protocol AF: A randomized trial
read more
New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of many retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision. That is why
read more Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more
Dr. Abbey Spoke About Vitrectomy and Light Adjustable Lenses at ASRS 2026
Texas Retina’s Ashkan Abbey, MD, FASRS, FAAO, participated in a panel discussion on the impact of vitrectomy on light adjustable lenses before final laser lock-in in post-cataract surgery patients at the 44th
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, our physicians have participated in more than 100 national clinical trials over the past 20+ years, offering our patients access to promising new treatments for a variety of retina
read more